Transition from Any Other Long‑Acting Injectable (LAI) Antipsychotic to INVEGA SUSTENNA® to INVEGA TRINZA®

Dose Information

Graph Information

^ Back to Top

Transition to INVEGA TRINZA® from Any Other LAI Antipsychotic (Any Other LAI Antipsychotic to INVEGA SUSTENNA® to INVEGA TRINZA®)

Consistent with the INVEGA TRINZA® Prescribing Information:

  • Clinically stable patients entering the INVEGA TRINZA® long-term maintenance study who were being treated with a long-acting injectable antipsychotic product (other than RISPERDAL CONSTA®) were transitioned to 234 mg of INVEGA SUSTENNA® administered in the deltoid muscle in place of the next scheduled injection.
  • INVEGA TRINZA® is to be used only after INVEGA SUSTENNA® has been established as adequate treatment for at least four months. Adjust the INVEGA SUSTENNA® dose (78 mg, 117 mg, 156 mg, or 234 mg) according to efficacy/tolerability needs of the patient. Conversion from the INVEGA SUSTENNA® 39 mg dose was not studied.
  • In order to establish a consistent maintenance dose, it is recommended that the last two doses of INVEGA SUSTENNA® be the same dosage strength before starting INVEGA TRINZA®.
  • Initiate INVEGA TRINZA® when the next INVEGA SUSTENNA® is scheduled with an INVEGA TRINZA® dose based on the previous INVEGA SUSTENNA® dose, using the equivalent 3.5-fold higher dose as shown in table below.

INVEGA TRINZA® Doses for Adult Patients Adequately Treated with INVEGA SUSTENNA®

If the Last Dose of INVEGA SUSTENNA® is:

Initiate INVEGA TRINZA® at the Following Dose:

78 mg

273 mg

117 mg

410 mg

156 mg

546 mg

234 mg

819 mg

Conversion from the INVEGA SUSTENNA® 39 mg dose was not studied.

  • INVEGA TRINZA® should be administered every 3 months.
  • If needed, dose adjustment can be made every 3 months in increments within the range of 273 mg to 819 mg based on individual patient tolerability and/or efficacy. Due to the long-acting nature of INVEGA TRINZA®, the patient’s response to an adjusted dose may not be apparent for several months.
  • In a long-term placebo-controlled randomized-withdrawal trial, the percentages of patients with schizophrenia entering the double-blind phase on each of the INVEGA TRINZA® dosage strengths were 4% for 273 mg, 9% for 410 mg, 49% for 546 mg, and 38% for 819 mg.
  • Since other LAI antipsychotics (other than RISPERDAL CONSTA®) are not related to the paliperidone compound, the cumulative plasma level curve will not reflect the plasma level contributions from the previous LAI antipsychotic treatment in this scenario.
  • Administration: For intramuscular injection only by a healthcare professional. Care should be taken to avoid inadvertent injection into a blood vessel.

INVEGA TRINZA® Prescribing Information []
INVEGA SUSTENNA® Prescribing Information []

Educational Dose Illustrator for:
INVEGA SUSTENNA® (paliperidone palmitate)
INVEGA TRINZA® (paliperidone palmitate)

The Educational Dose Illustrator can be used to visualize how dosing affects paliperidone plasma concentrations following administration of:


  • the treatment of schizophrenia in adults
  • the treatment of schizoaffective disorder in adults as monotherapy and as an adjunct to mood stabilizers or antidepressants


  • the treatment of schizophrenia in patients after they have been adequately treated with INVEGA SUSTENNA® for at least four months.

This resource simulates the paliperidone plasma concentrations over time resulting from different dosing scenarios that are set forth in the respective Prescribing Information for INVEGA SUSTENNA® and INVEGA TRINZA®. The Educational Dose Illustrator is intended to be used as a resource to foster a better understanding of, and educate healthcare professionals about, the dosing recommendations provided in the respective Prescribing Information for INVEGA SUSTENNA® and INVEGA TRINZA®. It is intended for educational purposes only.

Because the simulated patient paliperidone plasma levels shown in the dosing scenarios are based upon aggregated pharmacokinetic information from clinical studies, the simulations may not be representative of individual patient response.

Please Acknowledge

The information contained in this web site is intended for US healthcare professionals only. Privacy Policy.

Please Confirm


Thank you for visiting the Educational Dose Illustrator.

By clicking "Continue" below, you will be taken to a website where our Privacy Policy does not apply. You are solely responsible for your interactions with such websites.

We encourage you to read the Privacy Policy of every website you visit. Please view our Privacy Policy at your convenience.

Continue Cancel